LSPN Live: ‘Unimpressive’ Arthrex remedy fuels uncertainty

The unpredictable nature of the US legal landscape has arguably kept IP practitioners on tenterhooks over the past decade.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USPTO urges Vidal review of Arthrex petition

19 May 2022 The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

Big Pharma

LSPN Connect: Monetising your IP portfolio

15 February 2021 Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

article

LSPN Connect: how COVID crystallised Oxford Uni’s licensing mission

1 February 2021 The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.